Karyopharm Therapeutics

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Karyopharm reports robust revenue growth and strategic clinical advancements

Karyopharm Therapeutics demonstrated strong performance in revenue growth and clinical pipeline advancements, positioning them for continued success in 2023.
Strategic strengths in product portfolio, leadership, and innovation align well with opportunities in accelerating growth and exploring novel treatment approaches.
Challenges in differentiation, data updates, and dose optimization require focused strategies to overcome obstacles and drive sustainable growth.
Overall, Karyopharm's focus on patient outcomes, strategic expansion, and upcoming milestones indicate a positive trajectory for the company.

Karyopharm Therapeutics navigates revenue challenges while advancing pipeline innovations

Karyopharm Therapeutics faced revenue challenges due to PAP usage and discounts but showcased strong demand for XPOVIO and promising pipeline progress.
The company's financial stability was supported by expense reductions and total revenue of $38.7 million for Q1 2023.
Opportunities lie in commercial expansions, Phase III data advancements, and strategic product development efforts, positioning Karyopharm for future growth and innovation.

Karyopharm Therapeutics excels in Q2, eyes $2B peak revenues

Karyopharm Therapeutics showcased strong financial performance, strategic workforce reductions, and progress in pivotal Phase III trials during the Q2 earnings call. The company's focus on advancing novel SINE compounds and maintaining financial strength positions them well for future growth and value creation.

Karyopharm Therapeutics reports robust Q3 earnings and highlights growth prospects

Karyopharm Therapeutics showcased strong financial performance with revenue of $36 million and emphasized growth potential.
Promising Phase III trial data for myelofibrosis and endometrial cancer positions selinexor as a treatment paradigm changer.
Challenges include PAP impact from foundation closures, but opportunities lie in novel drug combinations and growth strategies.

Karyopharm meets revenue targets, eyes transformative outcomes in trials

Karyopharm Therapeutics delivered on revenue targets, showcasing strong performance and promising trial results in key indications.
While facing challenges in academic settings and financial obligations, the company's strategic strengths and growth opportunities position it well for the future.
With a focus on advancing Phase III trials, leveraging IP advantages, and exploring new treatment avenues, Karyopharm aims for continued innovation and market expansion.
Overall, Karyopharm's Q4 2023 Earnings Call reflects a balanced outlook with a solid foundation for growth and value creation in the biopharmaceutical sector.

Karyopharm Therapeutics reports strong Q1 performance and strategic refinancing

Karyopharm Therapeutics' Q1 2024 earnings call highlighted robust performance, strategic refinancing, and promising late-stage pipeline developments. While facing challenges in financial clarity and trial progress, the company is well-positioned to capitalize on growth opportunities through biomarker-driven patient selection and combination therapies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Early next year, Karyopharm expects to unveil pivotal clinical trial results that could send shares soaring.

Will Karyopharm’s Stock Take Off in 2020?

-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst® and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst®-Naïve and Revlimid®-Relapsed or -Refractory Myeloma with Progression-Free Survival of 12.2 Months --    -- Selinexor and Low Dose Dexamethasone Either Alone or in Combination with Velcade® or Kyprolis® Results in Responses in Six of Seven Patients Whose Myeloma Has Progressed Following Experimental CAR-T Therapy --

Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting

NEWTON, Mass., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 84,000 shares of Karyopharm’s common stock to eleven newly-hired employees, with a grant date of November 29, 2019.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4).

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).

Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great Choice

Karyopharm (KPTI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%

Karyopharm Therapeutics: Up, Up And Away

Karyopharm Therapeutics Inc.'s (KPTI) CEO Michael Kauffman on Q3 2019 Results - Earnings Call Transcript

NEWTON, Mass., Oct.  01, 2019  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 130,500 shares of Karyopharm’s common stock to fourteen newly-hired employees, with a grant date of September 30, 2019.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4).

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c) (4).

Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.

Karyopharm Signs $150M Royalty Agreement to Support Xpovio

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) posted a solid gain on Monday despite the pressure in the broader markets.

Even More Implied Analyst Upside for Karyopharm Therapeutics After Royalty Pact

-- Investment Expected to Extend Karyopharm’s Cash Runway into Middle of 2021 -- -- Investment Expected to Extend Karyopharm’s Cash Runway into Middle of 2021 --

Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million

NEWTON, Mass., Sept.  13, 2019  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical data for XPOVIO™ (selinexor) will be presented at the 17th International Myeloma Workshop (IMW) taking place September 12-15, 2019 in Boston.

Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop

NEWTON, Mass., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences: 

Karyopharm to Participate in Upcoming Investor Conferences

-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody --    -- In STORM, XPOVIO Achieved a 26% Overall Response Rate, 8.6 Month Median Overall Survival and 15.6 Month Median Survival in the 39% of Patients with Minimal Response or Better --

Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2019 Earnings Conference Call August 6, 2019 8:30 AM ET

Karyopharm Therapeutics Inc. (KPTI) CEO Dr. Michael Kauffman on Q2 2019 Results - Earnings Call Transcript

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Karyopharm Therapeutics (KPTI) Q2 Earnings Expected to Decline

Shares jump after the biopharma receives some praise from Wall Street.

Why Karyopharm Therapeutics Is Up Today

Amarin Corporation Plc

Alibaba

HealthEquity

Vonage Hlds

Looking for stocks to buy now? These seven companies are among the best stocks to invest in for their immaculate record from the Street's top analysts.

7 Stocks to Buy for Monster Growth in the Second Half of 2019

Karyopharm Therapeutics receives FDA accelerated approval for selinexor to treat patients with penta-refractory multiple myeloma.

Karyopharm's FDA Accelerated Approval For Cancer Drug Isn't The Only One On Deck

As of late, it has definitely been a great time to be an investor Karyopharm Therapeutics.

Will Karyopharm Therapeutics Continue to Surge Higher?

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) stock has skyrocketed more than 50% in the past week after the FDA approved the company’s Xpovio treatment for patients with multiple myeloma.

Large Option Trader Dumps Karyopharm Puts Following Xpovio Approval Rally

Shares of biotech companies Karyopharm Therapeutics and DBV Technologies jumped Friday after the former firm gained approval for a drug called Xpovio as a multiple myeloma treatment.
The post Why Investors In This Biotech Stock Are Breathing A Sigh Of Relief appeared first on Investor's Business Daily.

Why Investors In This Biotech Stock Are Breathing A Sigh Of Relief

After initial hiccups such as a tough FDA panel briefing document and a not-so-favorable panel verdict, Karyopharm Therapeutics Inc (NASDAQ: KPTI) managed to secure approval for its multiple myeloma treatment Xpovio three days ahead of the given PDUFA date.

HC Wainwright Hikes Karyopharm Price Target On Accelerated Drug Approval

Karyopharm (KPTI) gets accelerated FDA approval for oral Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Karyopharm Gets Accelerated FDA Approval for Myeloma Drug

Traders cheer after the company reports a regulatory win.

News for Karyopharm Therapeutics Stock (KPTI)